Battling COVID-19: Using Old Weapons for a New Enemy

Overview

Journal Trop Dis Travel Med Vaccines

Publisher Biomed Central

Specialty Infectious Diseases

Date 2020 May 27

PMID 32454984

Citations 14

Authors

Rohit Kumar

Nitin Gupta

Parul Kodan

Ankit Mittal

Manish Soneja

Naveet Wig

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19.

Citing Articles

Favipiravir Analogues as Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase, Combined Quantum Chemical Modeling, Quantitative Structure-Property Relationship, and Molecular Docking Study.

Latosinska M, Latosinska J Molecules. 2024; 29(2).

PMID: 38257352 PMC: 10818557. DOI: 10.3390/molecules29020441.

Autophagy and SARS-CoV-2-Old Players in New Games.

Ivanova T, Mariienko Y, Mehterov N, Kazakova M, Sbirkov Y, Todorova K Int J Mol Sci. 2023; 24(9).

PMID: 37175443 PMC: 10178552. DOI: 10.3390/ijms24097734.

Elucidating the Role of Noncovalent Interactions in Favipiravir, a Drug Active against Various Human RNA Viruses; a H-N NQDR/Periodic DFT/QTAIM/RDS/3D Hirshfeld Surfaces Combined Study.

Latosinska J, Latosinska M, Seliger J, Zagar V, Apih T, Grieb P Molecules. 2023; 28(8).

PMID: 37110542 PMC: 10147075. DOI: 10.3390/molecules28083308.

Anti-COVID-19 drugs, COVID-19 and anesthetics - The challenge for anesthesiologists.

Garg R, Yadav P J Anaesthesiol Clin Pharmacol. 2022; 38(Suppl 1):S140-S141.

PMID: 36060185 PMC: 9438829. DOI: 10.4103/joacp.JOACP_564_20.

COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries.

Pidiyar V, Kumraj G, Ahmed K, Ahmed S, Shah S, Majumder P Vaccine. 2022; 40(36):5302-5312.

PMID: 35914959 PMC: 9148927. DOI: 10.1016/j.vaccine.2022.05.065.

References

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Jung E, Nam S, Oh H, Jun S, Ro H, Kim B . Neutralization of Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In Vitro. Sci Rep. 2019; 9(1):8682. PMC: 6582152. DOI: 10.1038/s41598-019-45095-1. View

Cao J, Forrest J, Zhang X . A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res. 2014; 114:1-10. PMC: 7113785. DOI: 10.1016/j.antiviral.2014.11.010. View

Chan K, Lai S, Chu C, Tsui E, Tam C, Wong M . Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6):399-406. View

Preobrazhenskaya M, Olsufyeva E . Polycyclic peptide and glycopeptide antibiotics and their derivatives as inhibitors of HIV entry. Antiviral Res. 2006; 71(2-3):227-36. PMC: 7114112. DOI: 10.1016/j.antiviral.2006.04.008. View

Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View

Longley S, DUNNING R, Waldman R . Effect of isoprinosine against challenge with A(H3N2)-Hong Kong influenza virus in volunteers. Antimicrob Agents Chemother. 1973; 3(4):506-9. PMC: 444443. DOI: 10.1128/AAC.3.4.506. View

Teijaro J . The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. Curr Top Microbiol Immunol. 2014; 386:3-22. DOI: 10.1007/82_2014_411. View

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

10.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

11.

Chan J, Yao Y, Yeung M, Deng W, Bao L, Jia L . Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015; 212(12):1904-13. PMC: 7107395. DOI: 10.1093/infdis/jiv392. View

12.

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

13.

He R, Adonov A, Traykova-Adonova M, Cao J, Cutts T, Grudesky E . Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun. 2004; 320(4):1199-203. PMC: 7111066. DOI: 10.1016/j.bbrc.2004.06.076. View

14.

Devaux C, Rolain J, Colson P, Raoult D . New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. 2020; 55(5):105938. PMC: 7118659. DOI: 10.1016/j.ijantimicag.2020.105938. View

15.

Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

16.

Laing R, Gillan V, Devaney E . Ivermectin - Old Drug, New Tricks?. Trends Parasitol. 2017; 33(6):463-472. PMC: 5446326. DOI: 10.1016/j.pt.2017.02.004. View

17.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J . Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020; 6(10):1192-1198. PMC: 7185795. DOI: 10.1016/j.eng.2020.03.007. View

18.

Bhimraj A, Morgan R, Shumaker A, Lavergne V, Baden L, Cheng V . Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020; . PMC: 7197612. DOI: 10.1093/cid/ciaa478. View

19.

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

20.

Maieron A, Kerschner H . Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C. J Antimicrob Chemother. 2012; 67(10):2537-8. PMC: 7109765. DOI: 10.1093/jac/dks217. View